Royal Bank Of Canada Initiates Coverage on Charles River Laboratories International (NYSE:CRL)

Equities research analysts at Royal Bank Of Canada initiated coverage on shares of Charles River Laboratories International (NYSE:CRL) in a research report issued to clients and investors on Tuesday, MarketBeat Ratings reports. The firm set a “moderate buy” rating and a $215.00 price target on the medical research company’s stock. Royal Bank Of Canada’s target price indicates a potential upside of 18.89% from the stock’s previous close.

Other research analysts have also issued reports about the company. JPMorgan Chase & Co. lowered their price target on Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Monday. Bank of America raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 target price on the stock in a research note on Monday, December 15th. Barclays raised their target price on Charles River Laboratories International from $200.00 to $210.00 and gave the company an “overweight” rating in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Charles River Laboratories International in a research report on Wednesday, January 21st. Finally, Mizuho cut their price target on shares of Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating on the stock in a research note on Friday, February 20th. Eleven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $205.36.

Charles River Laboratories International Price Performance

Shares of CRL opened at $180.83 on Tuesday. The firm has a 50-day simple moving average of $168.66 and a two-hundred day simple moving average of $182.61. The stock has a market cap of $8.92 billion, a PE ratio of -61.09, a P/E/G ratio of 2.17 and a beta of 1.61. Charles River Laboratories International has a 1-year low of $99.80 and a 1-year high of $228.88. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.29 and a quick ratio of 1.02.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 EPS for the quarter, topping the consensus estimate of $2.33 by $0.06. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The firm had revenue of $994.23 million for the quarter, compared to analyst estimates of $986.98 million. During the same period in the prior year, the business posted $2.66 EPS. The business’s revenue for the quarter was down .8% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, analysts forecast that Charles River Laboratories International will post 9.36 EPS for the current year.

Institutional Investors Weigh In On Charles River Laboratories International

Several large investors have recently bought and sold shares of the stock. Tema Etfs LLC purchased a new position in shares of Charles River Laboratories International in the 4th quarter valued at about $26,000. Rothschild Investment LLC increased its stake in shares of Charles River Laboratories International by 82.4% during the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after buying an additional 84 shares during the period. Atlantic Union Bankshares Corp purchased a new stake in shares of Charles River Laboratories International during the third quarter worth approximately $31,000. Los Angeles Capital Management LLC acquired a new stake in Charles River Laboratories International in the fourth quarter valued at approximately $42,000. Finally, Sfam LLC purchased a new position in Charles River Laboratories International in the fourth quarter worth approximately $43,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.